MENLO PARK, CA--(Marketwire - December 19, 2007) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced the commencement of its Phase 3 trial with CORLUX for the treatment of endogenous Cushing's Syndrome. CORLUX is a cortisol receptor (GR-II) antagonist.
